|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400080363 |
|
最近更新日期: Date of Last Refreshed on: |
2024-01-26 17:26:25 |
|
注册时间: Date of Registration: |
2024-01-26 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
艾司氯胺酮改善右美托咪定和瑞芬太尼在脂肪抽吸麻醉中的镇静和镇痛效果 |
|
Public title: |
Subanesthetic Dose of Esketamine Improves the Sedative and Analgesic Effects of Dexmedetomidine and Remifentanil in Liposuction Anesthesia |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
艾司氯胺酮改善右美托咪定和瑞芬太尼在脂肪抽吸麻醉中的镇静和镇痛效果 |
|
Scientific title: |
Esketamine Improves the Sedative and Analgesic Effects of Dexmedetomidine and Remifentanil in Liposuction Anesthesia |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
陈皓天 |
研究负责人: |
魏灵欣 |
|
Applicant: |
Chen Haotian |
Study leader: |
Wei Linxin |
|
申请注册联系人电话: Applicant telephone: |
+86 183 1030 2371 |
研究负责人电话: Study leader's telephone: |
+86 155 2200 2357 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
zxchenhaotian@student.pumc.edu.cn |
研究负责人电子邮件: Study leader's E-mail: |
weilx3934@sina.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
北京市石景山区八大处路33号 |
研究负责人通讯地址: |
北京市石景山区八大处路33号 |
|
Applicant address: |
33 Badachu Road, Shijingshan District, Beijing |
Study leader's address: |
33 Badachu Road, Shijingshan District, Beijing |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
中国医学科学院整形外科医院 |
||
|
Applicant's institution: |
Plastic Surgery Hospital, Chinese Academy of Medical Sciences |
||
|
研究负责人所在单位: |
中国医学科学院整形外科医院 |
||
|
Affiliation of the Leader: |
Plastic Surgery Hospital, Chinese Academy of Medical Sciences |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
(2023)注册第(226)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中国医学科学院整形外科医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Plastic Surgery Hospital, Chinese Academy of Medical Sciences |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2023-12-29 00:00:00 |
||
|
伦理委员会联系人: |
裴晔 |
||
|
Contact Name of the ethic committee: |
Pei Ye |
||
|
伦理委员会联系地址: |
北京市石景山区八大处路33号 |
||
|
Contact Address of the ethic committee: |
33 Badachu Road, Shijingshan District, Beijing |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 10 5396 8034 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
中国医学科学院整形外科医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Plastic Surgery Hospital, Chinese Academy of Medical Sciences |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
北京市石景山区八大处路33号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
33 Badachu Road, Shijingshan District, Beijing |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自筹经费 |
||||||||||||||||||||||
|
Source(s) of funding: |
Self-raised |
||||||||||||||||||||||
|
Target disease: |
Sedative and Analgesic Anesthesia |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
上市后药物 | ||||||||||||||||||||||
|
Study phase: |
4 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
目前,脂肪抽吸术所应用的镇静镇痛麻醉方案是右美托咪定复合瑞芬太尼,但它们与呼吸抑制风险相关。为了平衡麻醉深度和呼吸安全,需要更优化的药物改善镇静方案,提升患者和手术团队的围术期满意度。艾司氯胺酮,因其具有麻醉和镇痛双重作用而被广泛应用,亚麻醉剂量的艾司氯胺酮能够减少围术期阿片类药物用量及相应并发症的发生率,同时具有潜在缓解患者围术期焦虑抑郁水平和改善睡眠障碍的作用。本研究目的旨在观察术中静脉输注艾司氯胺酮对于改善右美托咪定和瑞芬太尼在脂肪抽吸麻醉中的镇静和镇痛效果,为整形外科手术的临床镇静实践提供参考。 |
||||||||||||||||||||||
|
Objectives of Study: |
Currently, dexmedetomidine combined with remifentanil is used as a sedative and analgesic regimen for liposuction, but they are associated with a risk of respiratory depression. In order to balance the depth of anesthesia and respiratory safety, a more optimized drug to improve sedation program is needed to improve the perioperative satisfaction of patients and surgical teams. Esmketamine has been widely used due to its dual effects of anesthesia and analgesia. The subanesthetic dose of esmketamine can reduce the perioperative opioid consumption and the incidence of corresponding complications, and has the potential to alleviate the level of anxiety and depression and improve sleep disorders in patients during the perioperative period. The aim of this study is to observe the efficacy of intraoperative intravenous infusion of esketamine in improving the sedative and analgesic effects of dexmedetomidine and remifentanil in liposuction anesthesia, and to provide reference for clinical sedation practice in plastic surgery. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
(1)年龄18 ~ 60岁的男性或女性 (2)ASA分级:I~II级 (3)术前与患者签署知情同意书 |
||||||||||||||||||||||
|
Inclusion criteria |
(1) Males or females aged 18-60 years (2)The ASA I ~ II grade (3)Sign an informed consent form with the patient before surgery |
||||||||||||||||||||||
|
排除标准: |
(1)术前急性和(或)慢性疼痛 (2)术后48 h内服用镇痛药物 (3)有先天性心脏病、心律失常或高血压病史 (4)近1个月有严重肺部疾病 (5)艾氯胺酮禁忌证或过敏 (6)既往有严重精神或神经系统疾病、药物或精神药物滥用史 (7)认知功能障碍或沟通障碍 |
||||||||||||||||||||||
|
Exclusion criteria: |
(1) acute and/or chronic pain before surgery (2) taking analgesic drugs within 48 hours of surgery (3) history of congenital heart disease, arrhythmia, or hypertension (4) severe lung disease in the past month (5) contraindications or allergy to esketamine (6) history of severe mental or neurological diseases, drug or psychotropic drug abuse (7) cognitive dysfunction or inability to communicate |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-12-31 00:00:00至 To 2024-03-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2024-01-30 00:00:00 至 To 2024-03-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
计算机生成的随机化数字表 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
A computer-generated randomized digital table |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
双盲 |
|
Blinding: |
Double-blinded |
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
不共享 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Do not share metadata |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
采用CRF病例记录表和EXCEL表格收集和管理数据 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data were collected and managed by using CRF and EXCEL |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |